Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detectio… (NCT07430501) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detection, Personalised Treatment, and Long-term Monitoring of Patients Across the Full Spectrum of Metabolic-associated Fatty Liver Disease (MAFLD).
Spain7,720 participantsStarted 2026-02-23
Plain-language summary
The goal of this observational study is to create a detailed virtual model to better understand how Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) develops. This model will also help predict heart problem at different stage of the disease.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. \- Clinical Use Case 1: Liver disease staging in MASLD patients - Prediction model of fibrosis changes (progression and regression), with ability to distinguish between fast and non-fast fibrosis progression among MASLD patients.
✓. \- Clinical Use case 2: MASLD and progression of cardiovascular diseases
✓.1- Clinical Use case 3-TIPS: Patients with cirrhosis and portal hypertension who receive TIPS placement.
✓.2.- Clinical Use Case 3-LT: Patients with cirrhosis and portal hypertension who received liver transplantation.
✓.- Clinical Use Case 4: Prediction of cardiac complications due to HCC treatments\* (\*Note: includes surgical interventions, ablation, TACE, TARE, SIRT and immunotherapies)
✓.- Other populations (participation in control arms)
Exclusion criteria
✕. \- Clinical Use Case 1: Liver disease staging in MASLD patients - Prediction model of fibrosis changes (progression and regression), with ability to distinguish between fast and non-fast fibrosis progression among MASLD patients.
✕. \- Clinical Use case 2: MASLD and progression of cardiovascular diseases
✕.1- Clinical Use case 3-TIPS: Patients with cirrhosis and portal hypertension who receive TIPS placement.
✕.2.- Clinical Use Case 3-LT: Patients with cirrhosis and portal hypertension who received liver transplantation.
✕
What they're measuring
1
Liver disease progression and regression in MASLD patients
Timeframe: From baseline assessment to last available follow-up (minimum 1 year, up to 5 years)
Trial details
NCT IDNCT07430501
SponsorHospital Universitari Vall d'Hebron Research Institute
.- Clinical Use Case 4: Prediction of cardiac complications due to HCC treatments\* (\*Note: includes surgical interventions, ablation, TACE, TARE, SIRT and immunotherapies)
✕.- Other populations (participation in control arms)